DelveInsight’s, “Spasticity Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spasticity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Spasticity Treatment Landscape @ Spasticity Pipeline Outlook

Key Takeaways from the Spasticity Pipeline Report

• On 20 August 2025, Celgene conducted a study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity.
• On 03 August 2025, Ipsen announced a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
• DelveInsight’s Spasticity pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Spasticity treatment.
• The leading Spasticity Companies such as Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc. and others.
• Promising Spasticity Pipeline Therapies such as IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Baclofen, CORETOX®, BOTOX® and others.

Stay informed about the cutting-edge advancements in Spasticity treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Spasticity Clinical Trials Assessment

Spasticity Emerging Drugs Profile

• MTR-601: Motric Bio

MTR-601, represents a potential first-in-class antispastic therapy with a unique mechanism of action that directly targets the contractile protein – myosin 2 – in fast-twitch skeletal muscle. As an oral, selective inhibitor, MTR-601 is designed to offer a non-invasive approach for the treatment of cervical dystonia, targeting fast-twitch muscle fibers with the potential to decrease stiffness and potentially improve physical function. MTR-601 on a robust body of preclinical data that demonstrates initial activity in selectively relaxing fast-twitch skeletal muscle subtypes. In a preclinical model, MTR-601 was also shown to improve gait function in spastic cerebral palsy. Currently, the drug is in Phase II stage of its development for the treatment of Spasticity.

• IPN10200: Ipsen

IPN10200 is a long‑acting botulinum neurotoxin candidate developed by Ipsen for the treatment of upper limb spasticity. Engineered for extended duration of effect, it aims to provide sustained relief from muscle hyperactivity by inhibiting acetylcholine release at neuromuscular junctions. As a targeted neurotoxin therapy, IPN10200 is designed to reduce muscle tone more consistently over time, potentially reducing injection frequency and improving patient convenience. Its development reflects Ipsen’s strategic focus on neuroscience and its commitment to advancing innovative therapeutic options in spasticity management. Currently, the drug is in Phase I/II stage of its development for the treatment of Spasticity.

The Spasticity Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
• Spasticity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.

Learn more about Spasticity Drugs opportunities in our groundbreaking Spasticity research and development projects @ Spasticity Unmet Needs

Spasticity Companies

Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc. and others.

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral

Spasticity Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we’re transforming the future of Musculoskeletal @ Spasticity Market Drivers and Barriers, and Future Perspectives

Scope of the Spasticity Pipeline Report

• Coverage- Global
• Spasticity Companies- Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc. and others.
• Spasticity Pipeline Therapies- IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Baclofen, CORETOX®, BOTOX® and others.
• Spasticity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Spasticity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Spasticity Pipeline on our website @ Spasticity Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Spasticity: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spasticity– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Mid Stage Products (Phase II)
10. MTR-601: Motric Bio
11. Early Stage Products (Phase I/II)
12. IPN10200: Ipsen
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Spasticity Key Companies
17. Spasticity Key Products
18. Spasticity- Unmet Needs
19. Spasticity- Market Drivers and Barriers
20. Spasticity- Future Perspectives and Conclusion
21. Spasticity Analyst Views
22. Spasticity Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spasticity-pipeline-insight